Novel Insights into the Prognosis and Immunological Value of the SLC35A (Solute Carrier 35A) Family Genes in Human Breast Cancer

Ta, Hoang Dang Khoa; Xuan, Do Thi Minh; Tang, Wanchun; Anuraga, Gangga; Ni, Yi-Chun; Pan, Syu-Ruei; Wu, Yung-Fu; Fitriani, Fenny; Hermanto, Elvira Mustikawati Putri; Athoillah, Muhammad; Andriani, Vivin; Ajiningrum, Purity Sabila; Wang, Chih‐Yang

doi:10.3390/biomedicines9121804

Cited by 16 publications

(16 citation statements)

References 70 publications

(81 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent CRISPR-Cas9 screening in vivo 37: 262-269 (2023) identified an increased resistance to the DNA-damaging agent cisplatin in the SLC35A2-deficient cells (15). MetaCore pathway analysis of SLC35A2 co-expressed genes suggests that SLC35A2 may play a role in cell cycle regulation (4). Nonetheless, we found that cell growth was not affected by modulation of SLC35A2 expression in the present study.…”

Section: Discussioncontrasting

confidence: 59%

See 1 more Smart Citation

Aberrant Expression of Solute Carrier Family 35 Member A2 Correlates With Tumor Progression in Breast Cancer

Liu

Cheng

Huang

et al. 2023

In Vivo

View full text Add to dashboard Cite

Background/Aim: A recent study suggested that solute carrier family 35 member A2 (SLC35A2) is related to poor prognosis in patients with breast cancer. SLC35A2 transports uridine diphosphate-galactose from the cytosol to the lumen of the endoplasmic reticulum and Golgi. Materials and Methods: Immunohistochemical expression of SLC35A2 was evaluated using tissue microarrays. Cell growth, migration, and invasion of breast cancer cells were examined following loss-and gain-of-expression of SLC35A2. Results: Normal breast tissue exhibited SLC35A2 immunoreactivity in the nucleus. A progressive increase in cytoplasmic expression from in situ carcinoma to invasive carcinoma was observed. There was a correlation between cytoplasmic SLC35A2 expression and breast cancer stage (p<0.001). MDA-MB-468 and MCF-7 cells transfected with SLC35A2 shRNA had unchanged cell viability but significantly reduced cell migration and invasion. In contrast, MDA-MB-231 and HCC1806 cells transfected with the SLC35A2 expression vector showed increased migration. Conclusion: Breast cancer progression is accompanied by differential expression patterns of SLC35A2. The migratory or invasive capacity of breast cancer cells is associated with SLC35A2 expression.

show abstract

Section: Discussioncontrasting

confidence: 59%

“…A recent bioinformatics study disclosed that SLC35A2 was substantially related to poor prognosis in patients with breast cancer (4). The human SLC35A2 gene is located on chromosome Xp11.23 and encodes the uridine diphosphate (UDP)-galactose transporter.…”

mentioning

confidence: 99%

Aberrant Expression of Solute Carrier Family 35 Member A2 Correlates With Tumor Progression in Breast Cancer

Liu

Cheng

Huang

et al. 2023

In Vivo

View full text Add to dashboard Cite

show abstract

“…Therefore, many studies in recent years have focused on analyzing the function of SLC35 family in diseases including cancer. Several literatures have pointed out that SLC35A3 plays an important role in the occurrence and development of T-cell lymphoblastoma, pancreatic cancer, and breast cancer, and can be used as an early warning marker for the above cancers [17][18][19]. The clinical signi cance of SLC35A3 in CRC…”

Section: Discussionmentioning

confidence: 99%

“…The solute carrier 35A (SLC35A) gene family to be pivotal in the occurrence and development of tumor. SLC35A3 is highly expressed in triple negative breast cancer (TNBC) cell lines HCC1395, HCC1187 and MDAMB436 [17]. Research shows that SLC35A3 is the pathogenic gene of T-cell lymphoblastoma [18].…”

Section: Introductionmentioning

confidence: 99%

Colorectal cancer with low SLC35A3 is associated with immune infiltrates and poor prognosis

Lü

Sun

Tang

et al. 2023

Preprint

View full text Add to dashboard Cite

The expression level of SLC35A3 is related to the prognosis of many cancers, but its role in colorectal cancer (CRC) is still unknown. The purpose of our research is to clarify the role of SLC35A3 in the CRC. The expression level of SLC35A3 in CRC was evaluated by Tumor Immune Estimate Resource (TIMER), The Cancer Genome Atlas (TCGA), Human Protein Atlas (HPA) and qRT-PCR experiment. TCGA data set was used to analyze the diagnostic and prognostic value of SLC35A3 in CRC. An overall survival model was constructed and validated based on the expression level of SLC35A3 and the results of multivariate analysis. cBioPortal tool is used to analyze SLC35A3 mutation in CRC, and UALCAN tool was used to analyze the promoter methylation level of SLC35A3 in CRC. In addition, the role of SLC35A3 in the CRC was determined by GO analysis, KEGG analysis, gene set enrichment analysis (GSEA), immune infiltration analysis and correlation analysis of immune checkpoints. Compared with adjacent normal tissues of CRC and colon epithelial cells , the expression of SLC35A3 in CRC tissues and CRC cell lines decreased. The low expression of SLC35A3 is related to N stage, pathological stage and lymph infiltration, and is not conducive to overall survival (OS) and disease specific survival (DSS). According to Receiver Operating Characteristic (ROC) analysis, SLC35A3 could be an important diagnostic biomarker for patients with CRC. The nomograph based on SLC35A3 is a model superior to a single prognostic factor. SLC35A3 has multiple types mutations in CRC, and its promoter methylation level is significantly reduced. GO and KEGG analysis display the SLC35A3 may involved in the transmembrane transporter activity, cell communication and the interaction of neural active ligand receptors. GSEA disclosed that SLC35A3 may participate in energy metabolism, DNA repair, cancer pathway. In addition, SLC35A3 is closely related to a variety of immune cell infiltration and immune checkpoint expression. The results of this study indicate that the decreased expression of SLC35A3 is closely related to poor prognosis of CRC and immune cell infiltration. SLC35A3 is a promising independent prognostic biomarker and a potential therapeutic target for CRC.

show abstract

“…The phenomenon of overexpression of SHCBP1 in breast cancer has been studied, and cellular experiments have demonstrated that this gene directly regulates breast cancer cell proliferation and promotes the cell cycle [ 44 ]. SLC35A2 is associated with hypoxia-inducible factors, heat shock proteins, transcription factors, and DNA damage-associated signaling and is involved in the regulation of neutrophil and macrophage polarization in breast cancer [ 45 ]. In summary, the majority of the genes associated with mRNAsi of breast cancer in this study are closely related to cancer development or immune regulation of breast cancer, and it is reasonable to use this constructed prognostic model for clinical prognostic guidance.…”

Section: Discussionmentioning

confidence: 99%

Construction and Validation of a Prognostic Model Based on mRNAsi-Related Genes in Breast Cancer

Zhao

Lin

2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Background. Breast cancer is a big threat to the women across the world with substantial morbidity and mortality. The pressing matter of our study is to establish a prognostic gene model for breast cancer based on mRNAsi for predicting patient’s prognostic survival. Methods. From The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, we downloaded the expression profiles of genes in breast cancer. On the basis of one-class logistic regression (OCLR) machine learning algorithm, mRNAsi of samples was calculated. Kaplan-Meier (K-M) and Kruskal-Wallis (K-W) tests were utilized for the assessment of the connection between mRNAsi and clinicopathological variables of the samples. As for the analysis on the correlation between mRNAsi and immune infiltration, ESTIMATE combined with Spearman test was employed. The weighted gene coexpression network analysis (WGCNA) network was established by utilizing the differentially expressed genes in breast cancer, and the target module with the most significant correlation with mRNAsi was screened. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted to figure out the biological functions of the target module. As for the construction of the prognostic model, univariate, least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analyses were performed on genes in the module. The single sample gene set enrichment analysis (ssGSEA) and tumor mutational burden were employed for the analysis on immune infiltration and gene mutations in the high- and low-risk groups. As for the analysis on whether this model had the prognostic value, the nomogram and calibration curves of risk scores and clinical characteristics were drawn. Results. Nine mRNAsi-related genes (CFB, MAL2, PSME2, MRPL13, HMGB3, DCTPP1, SHCBP1, SLC35A2, and EVA1B) comprised the prognostic model. According to the results of ssGSEA and gene mutation analysis, differences were shown in immune cell infiltration and gene mutation frequency between the high- and low-risk groups. Conclusion. Nine mRNAsi-related genes screened in our research can be considered as the biomarkers to predict breast cancer patients’ prognoses, and this model has a potential relationship with individual somatic gene mutations and immune regulation. This study can offer new insight into the development of diagnostic and clinical treatment strategies for breast cancer.

show abstract

Novel Insights into the Prognosis and Immunological Value of the SLC35A (Solute Carrier 35A) Family Genes in Human Breast Cancer

Cited by 16 publications

References 70 publications

Aberrant Expression of Solute Carrier Family 35 Member A2 Correlates With Tumor Progression in Breast Cancer

Aberrant Expression of Solute Carrier Family 35 Member A2 Correlates With Tumor Progression in Breast Cancer

Colorectal cancer with low SLC35A3 is associated with immune infiltrates and poor prognosis

Construction and Validation of a Prognostic Model Based on mRNAsi-Related Genes in Breast Cancer

Contact Info

Product

Resources

About